Evaluation of Intravenous Ascorbic Acid

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase I study will be conducted in 2 parts to examine safety and pharmacokinetics of escalating doses of intravenous ascorbic acid (AA) first in healthy volunteers followed by evaluation in oncology subjects. The study will be conducted in the Program in Integrative Medicine Infusion Clinic at the University of Kansas Medical Center in conjunction with the Program in Integrative Medicine, Kansas Cancer Research Institute, Department of Pharmacy, Department of Medical Oncology, the Division of Surgical Oncology,and with consultants from the NIH, and FDA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pharmacokinetics Study of Intravenous Ascorbic Acid

NCT02534753

Pharmacokinetics

COMPLETED PHASE1

Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients

NCT02455180

Multiple Organ Failure Sepsis Systemic Inflammatory Response Syndrome +1 more

COMPLETED PHASE4

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627

Healthy

COMPLETED PHASE1

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

NCT00099450

Cardiovascular Disease

COMPLETED PHASE1

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

NCT03960502

Healthy Male Participants

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to examine what happens when Vitamin C enters into the body, and the speed and ways it travels through the body, and the rate at which it exits the body in the urine. It is also necessary to determine if it is safe to give Intravenous Vitamin C at high doses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety and Pharmacokinetics of Intravenous Ascorbate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase I, IV Vitamin C Healthy Normals

Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.

Group Type EXPERIMENTAL

IV Vitamin C

Intervention Type DRUG

We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.

If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.

IV Vitamin C

Intervention Type DRUG

There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.

Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.

Phase 1 IV Vitamin C- Cancer Patients

Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.

Group Type EXPERIMENTAL

IV Vitamin C

Intervention Type DRUG

We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.

If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.

IV Vitamin C

Intervention Type DRUG

There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.

Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IV Vitamin C

We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.

If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks.

Intervention Type DRUG

IV Vitamin C

There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.

Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IV Ascorbate IV Ascorbate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults age 21 or older
* Laboratory: ANC ≥1,500/mm3,

* Hemoglobin \> 8g/dL,
* platelet ≥ 100,000/mm3,
* total bilirubin ≤ 1.5 mg/dL,
* creatinine ≤2.0 mg/dL,
* transaminase (AST/ALT) ≤2.5X upper limit,
* urine uric acid \< 1,000mg/d,
* urine pH \<6,
* urine oxalate \<60 mg/d.
* Participants who have no language barrier, are cooperative, and can give informed consent before entering the study after being informed of the medications and procedures to be used in this study may participate.

Exclusion:

* Glucose-6-phosphate-dehydrogenase (G6PD) deficiency
* History of bleeding disorder
* History of oxalate renal calculi; urine oxalate level \> 60 mg/d at baseline
* History of iron overload or hemochromatosis
* Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate.
* Co-morbid condition that would affect survival: end stage congestive heart failure, unstable angina, myocardial infarction within 6 weeks of study, uncontrolled blood sugars ≥ 300 mg/dL, participants with known chronic active hepatitis or cirrhosis.
* Participants who consume an excess of alcohol or abuse drugs (an excess of alcohol is defined as more than four of any one of the following per day: 30mL distilled spirits, 340mL beer, or 120mL wine) will not be allowed.
* Participants who smoke tobacco products will not be allowed to participate.

PART 2 ELIGIBILITY CRITERIA

Inclusion:

* Oncology participants must have histologically or cytologically diagnosed malignancy.
* The oncology participants must be age 21 or older and screened for eligibility and have study approved by treating oncologist.
* Oncology participants must be unwilling or ineligible for further radiation or chemotherapy at the time of enrollment into study.
* Participants must be without evidence of active spinal cord compression and have predicted lifespan of 6-months or more.
* ECOG Performance Status 0-2

* Eastern Cooperative Oncology Group Performance Status
* Grade 0 = Fully active, able to carry on all pre-disease activities without restriction
* Grade 1= Restricted in physical strenuous activity but ambulatory and able to carry out work of a light or sedentary nature e.g. light housework, office work
* Grade 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
* Laboratory:

* ANC ≥1,500/mm3,
* Hemoglobin \> 8g/dL,
* platelet ≥ 100,000/mm3,
* total bilirubin ≤ 1.5 mg/dL,
* creatinine ≤2.0 mg/dL,
* transaminase (AST/ALT) ≤2.5X upper limit,
* urine uric acid \< 1,000mg/d, urine pH \<6,
* urine oxalate \<60 mg/d.
* Participants who have no language barrier, are cooperative, and can give informed consent before entering the study after being informed of the medications and procedures to be used in this study may participate.

Exclusion:

* Glucose-6-phosphate-dehydrogenase (G6PD) deficiency
* Currently receiving chemotherapy or radiation therapy
* History of bleeding disorder
* History of oxalate renal calculi; urine oxalate level \> 60 mg/d at baseline
* History of iron overload or hemochromatosis
* Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate.
* ECOG Performance Status of 3-4

* Grade 3 = Capable of only limited self care, confined to bed or chair more than 50% of waking hours.
* Grade 4 = Completely disabled. Cannot carry on any self care. Totally confined to bed or chair) and in terminal stages of disease.
* Co-morbid condition that would affect survival: end stage congestive heart failure, unstable angina, myocardial infarction within 6 weeks of study, uncontrolled blood sugars ≥ 300 mg/dL, participants with known chronic active hepatitis or cirrhosis.
* Those who consume an excess of alcohol or abuse drugs (an excess of alcohol is defined as more than four of any one of the following per day: 30mL distilled spirits, 340mL beer, or 120mL wine) will not be allowed.
* Those who smoke tobacco products will not be allowed to participate.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes